JPWO2020219743A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020219743A5
JPWO2020219743A5 JP2021563213A JP2021563213A JPWO2020219743A5 JP WO2020219743 A5 JPWO2020219743 A5 JP WO2020219743A5 JP 2021563213 A JP2021563213 A JP 2021563213A JP 2021563213 A JP2021563213 A JP 2021563213A JP WO2020219743 A5 JPWO2020219743 A5 JP WO2020219743A5
Authority
JP
Japan
Prior art keywords
nmosd
medicament
administered
medicament according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529743A (ja
JP2022529743A5 (https=
JP7779738B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029613 external-priority patent/WO2020219743A2/en
Publication of JP2022529743A publication Critical patent/JP2022529743A/ja
Publication of JPWO2020219743A5 publication Critical patent/JPWO2020219743A5/ja
Publication of JP2022529743A5 publication Critical patent/JP2022529743A5/ja
Priority to JP2025120173A priority Critical patent/JP2025157413A/ja
Application granted granted Critical
Publication of JP7779738B2 publication Critical patent/JP7779738B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563213A 2019-04-24 2020-04-23 自己免疫疾患を治療するための抗cd19抗体の使用 Active JP7779738B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120173A JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗cd19抗体の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US62/838,093 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US62/843,096 2019-05-03
US201962858495P 2019-06-07 2019-06-07
US62/858,495 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120173A Division JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗cd19抗体の使用

Publications (4)

Publication Number Publication Date
JP2022529743A JP2022529743A (ja) 2022-06-23
JPWO2020219743A5 true JPWO2020219743A5 (https=) 2023-09-14
JP2022529743A5 JP2022529743A5 (https=) 2023-09-14
JP7779738B2 JP7779738B2 (ja) 2025-12-03

Family

ID=72940915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563213A Active JP7779738B2 (ja) 2019-04-24 2020-04-23 自己免疫疾患を治療するための抗cd19抗体の使用
JP2025120173A Pending JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗cd19抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120173A Pending JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗cd19抗体の使用

Country Status (12)

Country Link
US (1) US20220204617A1 (https=)
EP (1) EP3959241A4 (https=)
JP (2) JP7779738B2 (https=)
KR (1) KR20220004113A (https=)
CN (1) CN113939532A (https=)
AU (1) AU2020263418A1 (https=)
BR (1) BR112021020924A2 (https=)
CA (1) CA3136487A1 (https=)
IL (1) IL287385A (https=)
MX (1) MX2021012870A (https=)
SG (1) SG11202111429UA (https=)
WO (1) WO2020219743A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of anti-CD19 antibody to treat myasthenia gravis
KR20250044695A (ko) 2022-07-27 2025-04-01 비엘라 바이오, 인크. 이네빌리주맙 및 지속적인 b-세포 고갈을 위한 이의 사용 방법
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
SI2066349T1 (sl) * 2006-09-08 2012-08-31 Medimmune Llc Humanizirana anti-cd19 protitelesa in njihova uporaba v zdravljenju tumorjev, transplantacijah in avtoimunih boleznih
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
CN104640560A (zh) * 2012-03-12 2015-05-20 米迪缪尼有限公司 用抗-cd19抗体治疗多发性硬化症
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Similar Documents

Publication Publication Date Title
US12383521B2 (en) Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
Chan Optic neuritis in multiple sclerosis
DK201600003Y3 (da) Lavfrekvent glatiramer-acetat-terapi
Fragoso et al. Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years
Tzermpos et al. Transient delayed facial nerve palsy after inferior alveolar nerve block anesthesia
US20140030331A1 (en) Method of treating multiple sclerosis
Coelho et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients
US20250188158A1 (en) Treatment of Parkinson's Disease
Kaur et al. Optic neuritis and the neuro‐ophthalmology of multiple sclerosis
Gilden Varicella-zoster virus infections
JP2012210413A (ja) アルツハイマー病の静脈内免疫グロブリン処置における脳室拡大速度の使用
Lopalco et al. Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis
Ndiaye et al. Cochleovestibular impairment in pediatric Cogan’s syndrome
JPWO2020219743A5 (https=)
Miralles et al. Pure sensory Guillain-Barré syndrome
JP6464421B2 (ja) 慢性外傷性脳障害iiを予防及び/又は治療する方法
Penha et al. Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
JP2023534916A (ja) 視神経脊髄炎スペクトラム障害を治療する方法
Arshi et al. The first rapid onset optic neuritis after measles–rubella vaccination: case report
Spalice et al. Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update
US20240270830A1 (en) Methods for treating alzheimer's disease
JPWO2022094334A5 (https=)
Capo' et al. Efficacy and Tolerability of Solifenacin in Patients Aged⩾ 65 Years with Overactive Bladder: Post-Hoc Analysis of 2 Open-Label Studies
Buraga et al. Clinical response to intravenous immunoglobulin in acute inflammatory demyelinating polyradiculoneuropathy
RU2021134020A (ru) Применение антитела к cd19 для лечения аутоиммунного заболевания